Nicolas Ansermot

Nicolas Ansermot

Auto-generated profile, based on publicly available information

Nicolas Ansermot

Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Journal of Chromatography A
Verified
Journal Article
Closed access
NANicolas Ansermot
Nicolas Ansermot
MBMarlyse Brawand-Amey
Marlyse Brawand-Amey
AKAstrid Kottelat
Astrid Kottelat
CEChin B. Eap
Chin B. Eap


15 March 2022 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
MSMichal Smogur
Michal Smogur
AOAlice Onesanu
Alice Onesanu
KPKerstin Jessica Plessen
Kerstin Jessica Plessen
CEChin B. Eap
Chin B. Eap
NANicolas Ansermot
Nicolas Ansermot
Objectives: The decision to prescribe a medication and the choice of which one are often complex, particularly in the field of child and adolescent psychiatry where evidence is scarce. The aim of this review is to provide a synthesis of psychotropic drugs approved in children and adolescents for psychiatric indications in several countries. Methods: All psychopharmacological treatments used in child and adolescent psychiatry, approved by at least one regulatory agency from Switzerland, the United Kingdom, France, the European Union, or the United States, were considered. A comprehensive review of the summaries of product characteristics was performed. Results: A total of 143 psychotropic drugs were included: 47 anxiolytics/hypnotics, 45 antidepressants, 37 antipsychotics, 10 medications for attention-deficit/hyperactivity disorder (ADHD), and 4 mood stabilizers. Only a few of these drugs were approved for use in children or adolescents (38%) at least for a single psychiatric diagnosis in at least one country. The therapeutic class with the lowest rate of approved status was antidepressants (20%), followed by mood stabilizers (25%), anxiolytics/hypnotics (28%), antipsychotics (57%), and medications for ADHD (100%). Important differences in approved diagnoses, ages, and doses were observed between regulatory agencies. Tables presenting drugs for approved diagnoses based on age and regulatory agencies are presented in this article. Drugs classified by regulatory agencies, with complete data on diagnoses, ages, doses, pharmaceutical forms, and particular restrictions, are presented as Supplementary Material. Conclusion: This article provides an overview to prescribers with respect to the approved medications in children and adolescents in selected European countries and the United States.

1 July 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
EWEtienne Weisskopf
Etienne Weisskopf
Alice PanchaudAlice Panchaud
Alice Panchaud
KNKim An Nguyen
Kim An Nguyen
DGDelphine Grosjean
Delphine Grosjean
JHJean-Michel Hascoët
Jean-Michel Hascoët
NANicolas Ansermot
Nicolas Ansermot

1 January 2019 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
PDF file
NANicolas Ansermot
Nicolas Ansermot
MBMeredith Bochatay
Meredith Bochatay
JSJürg Schläpfer
Jürg Schläpfer
MGMehdi Gholam
Mehdi Gholam
AGAriane Gonthier
Ariane Gonthier
CEChin B Eap
Chin B Eap
Psychiatric patients are at risk of cardiovascular diseases, and many psychotropic drugs can prolong QTc interval. Requirements for electrocardiogram (ECG) monitoring have been set up in our psychiatric university hospital. The objective of this study was to determine the proportion of adult patients who had an ECG during their hospitalization, the prevalence of ECG abnormalities, the evolution of the QTc after admission, and the risk factors for QTc prolongation. Retrospective analysis of ECGs and clinical data of all patients with a complete hospitalization in 2015. Assessment of the influence of covariates on QTc using linear mixed-effects models. At least one ECG (n = 600) was performed during 37.6% of the stays (n = 1198) and in 45.5% of the patients (n = 871). Among the patients with an ECG, 17.9% had significant ECG abnormalities, including 7.6% with a prolonged QTc. QTc measured at admission and during hospitalization did not change significantly (n = 46, 419.4 ± 29.7 ms, 417.2 ± 27.6 ms, p = 0.71). In the multivariate model (292 patients, 357 ECGs), the covariates significantly associated with the QTc were gender (+15.9 ms if female, p < 0.0001), age (+0.4 ms/year, p = 0.0001), triglyceride levels (+5.7 ms/mmol/l, p = 0.005), and drugs with known risk of torsades de pointes (+6.2 ms if ⩾1 drug, p = 0.028). The prevalence of hospitalized psychiatric patients with an abnormal ECG indicates that ECGs should be performed systematically in this population. Prescription of psychotropic drugs should be done cautiously, particularly in patients with QTc prolongation risk factors.

1 August 2009 in Journal of Chromatography B
Verified
Journal Article
Closed access
NANicolas Ansermot
Nicolas Ansermot
SRSerge Rudaz
Serge Rudaz
MBMarlyse Brawand-Amey
Marlyse Brawand-Amey
SFSandrine Fleury-Souverain
Sandrine Fleury-Souverain
JVJean-Luc Veuthey
Jean-Luc Veuthey
CEChin B. Eap
Chin B. Eap